Dr. Naresh P. Singh, MD
Pulmonology (Pulmonary Disease Physician)
2000 Wellness Way
Las Vegas, NV 89106
Who else practices at this address →
Clark County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Nevada School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 387
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of Nevada School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NV license 5713
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mountainview Hospital Las Vegas, NV
- Summerlin Hospital Medical Center Las Vegas, NV
- University Medical Center Las Vegas, NV
- Valley Hospital Medical Center Las Vegas, NV
- Centennial Hills Hospital Medical Center Las Vegas, NV
Medical groups
- Pulmonary Associates Inc (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 387
- Services billed
- 1,571
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,236 | 261 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 179 | 168 |
| Established patient office or other outpatient visit, 20-29 minutes | 92 | 74 |
| Established patient office or other outpatient visit, 30-39 minutes | 83 | 61 |
| Test to measure expiratory airflow and volume | 60 | 57 |
| Established patient office or other outpatient visit, 10-19 minutes | 55 | 43 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 50 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 40 | 25 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 26 | 16 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Las Vegas, NV | 441 |
| Prednisone Other prescribers in Las Vegas, NV | 334 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Las Vegas, NV | 267 |
| Montelukast Sodium Other prescribers in Las Vegas, NV | 201 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Las Vegas, NV | 174 |
| Opsumit (macitentan) | 147 |
| Ofev (nintedanib esylate) | 131 |
| Prolastin C (alpha-1-proteinase inhibitor) | 114 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Las Vegas, NV | 98 |
| Azithromycin Other prescribers in Las Vegas, NV | 91 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 35 payments worth $11,559 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $8,369 |
|---|---|
| Grifols USA, LLC | $2,274 |
| Actelion Pharmaceuticals US, Inc. | $253 |
| United Therapeutics Corporation | $224 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $208 |
| Merck Sharp & Dohme LLC | $147 |
| Verona Pharma, Inc. | $51.95 |
| Bayer HealthCare Pharmaceuticals Inc. | $16.15 |
| Compensation for services other than consulting (speaking, faculty) | $9,980 |
|---|---|
| Food and Beverage | $1,448 |
| Education | $78.99 |
| Travel and Lodging | $52.54 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Grifols USA, LLC Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) Prolastin-C Liquid · Pulmonology | $2,140 |
| AstraZeneca Pharmaceuticals LP Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $2,040 |
| AstraZeneca Pharmaceuticals LP Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) BREZTRI · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Actelion Pharmaceuticals US, Inc. Apr 3, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $78.99 |
| AstraZeneca Pharmaceuticals LP Apr 24, 2025 | Travel and Lodging BREZTRI · Respiratory · travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $43.30 |
| Grifols USA, LLC Nov 18, 2025 | Travel and Lodging Prolastin-C Liquid · Pulmonology · travel to Las Vegas, NV | $9.24 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $185,202 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose…
AstraZeneca Pharmaceuticals LP - Ph III OLE of Astegolimab in COPD
Genentech, Inc. - A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Verona Pharma, Inc. - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209 - Ph IIb of Astegolimab in COPD
Genentech, Inc. - A multi-center, randomized, double-blind, parallel-group, placebo-cont
GlaxoSmithKline, LLC. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.